A research team led by Dr. Der-Yang Cho, Superintendent of China Medical University Hospital (Taiwan), in collaboration with Shine-On Biomedical Co., has developed the world’s first targeted exosome drug delivery platform aimed at HLA-G, marking a major milestone in the field of precision oncology. The novel platform, named SOB100, has completed preclinical studies and demonstrated promising efficacy in treating aggressive cancers such as breast cancer and glioblastoma.
The team’s findings were published in the prestigious journal Nature Communications, and on March 8, 2025, the platform received approval from the U.S. Food and Drug Administration (FDA) to begin Phase I clinical trials in humans.
